The Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will reconvene a Special Meeting of Shareholders (the “Special Meeting”) on November 7, 2025, at ...

The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will hold a Special Meeting of Shareholders (the “Special Meeting”) on October 31, 2025, at 12 p.m. ET ...

公司活动安排 - 管理层将于2025年9月16日13:30（东部时间）在第三季度虚拟投资者峰会上进行演示并参与一对一投资者会议 [1][2] - 演示由公司总裁兼首席执行官Paul V Goode博士主持 [2] - 活动主办方为Investor Summit Group 可通过其平台进行投资者注册 [2] 公司业务定位 - 公司专注于为糖尿病患者设计、开发和商业化新型技术 [1][2] - 当前核心产品为长期植入式连续血糖监测系统（CBGM） [2][3] 技术产品特性 - 监测系统采用完全植入式设计 无需体外佩戴组件且仅需极少量校准 [3] - 传感器使用寿命达3年 可实现持续血糖水平监测 [3] - 该设备目前属于研究阶段设备 根据美国联邦法律规定仅限研究用途 [3]